TW201615217A - 抗生素藥物臨床新應用 - Google Patents
抗生素藥物臨床新應用 Download PDFInfo
- Publication number
- TW201615217A TW201615217A TW104134908A TW104134908A TW201615217A TW 201615217 A TW201615217 A TW 201615217A TW 104134908 A TW104134908 A TW 104134908A TW 104134908 A TW104134908 A TW 104134908A TW 201615217 A TW201615217 A TW 201615217A
- Authority
- TW
- Taiwan
- Prior art keywords
- hcl
- antibiotic
- hydrochloride
- group
- cancer
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 229940079593 drug Drugs 0.000 title claims abstract description 51
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 50
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 27
- 239000003242 anti bacterial agent Substances 0.000 claims description 57
- 229940088710 antibiotic agent Drugs 0.000 claims description 52
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 29
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 20
- 229930182555 Penicillin Natural products 0.000 claims description 16
- 229940049954 penicillin Drugs 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 229960003276 erythromycin Drugs 0.000 claims description 14
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 12
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 12
- 229930186147 Cephalosporin Natural products 0.000 claims description 11
- 229940124587 cephalosporin Drugs 0.000 claims description 11
- 150000001780 cephalosporins Chemical class 0.000 claims description 11
- 230000000843 anti-fungal effect Effects 0.000 claims description 9
- 229940121375 antifungal agent Drugs 0.000 claims description 9
- IOVGROKTTNBUGK-SJKOYZFVSA-N (1S,2R)-ritodrine Chemical compound N([C@H](C)[C@@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJKOYZFVSA-N 0.000 claims description 8
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 8
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 8
- 229960003942 amphotericin b Drugs 0.000 claims description 8
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 8
- 229960005361 cefaclor Drugs 0.000 claims description 8
- 229960005091 chloramphenicol Drugs 0.000 claims description 8
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 8
- MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 claims description 8
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims description 8
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 claims description 8
- 229960005205 prednisolone Drugs 0.000 claims description 8
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 8
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 8
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims description 7
- 229960004191 artemisinin Drugs 0.000 claims description 7
- 229930101531 artemisinin Natural products 0.000 claims description 7
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229940072172 tetracycline antibiotic Drugs 0.000 claims description 5
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 4
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims description 4
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims description 4
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 4
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 claims description 4
- OWFJMIVZYSDULZ-PXOLEDIWSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-PXOLEDIWSA-N 0.000 claims description 4
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 claims description 4
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 claims description 4
- NYEPHMYJRNWPLA-UHFFFAOYSA-N (6-amino-2-ethoxyacridin-9-yl)azanium;2-hydroxypropanoate;hydrate Chemical compound O.CC(O)C([O-])=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3[NH+]=C21 NYEPHMYJRNWPLA-UHFFFAOYSA-N 0.000 claims description 4
- KEQFDTJEEQKVLM-JUODUXDSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydron;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 KEQFDTJEEQKVLM-JUODUXDSSA-N 0.000 claims description 4
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 4
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 4
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 4
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical group CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 claims description 4
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical compound C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 claims description 4
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims description 4
- HAAITRDZHUANGT-UHFFFAOYSA-N 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 HAAITRDZHUANGT-UHFFFAOYSA-N 0.000 claims description 4
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 4
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 claims description 4
- MPIPASJGOJYODL-UHFFFAOYSA-N 1-{2-[(2,6-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-UHFFFAOYSA-N 0.000 claims description 4
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 4
- MFBPRQKHDIVLOJ-AFFLPQGKSA-N 133868-46-9 Chemical compound Cl.CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 MFBPRQKHDIVLOJ-AFFLPQGKSA-N 0.000 claims description 4
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 claims description 4
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 claims description 4
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 claims description 4
- KGWHMDCQVDMTNZ-UHFFFAOYSA-N 2-(butylcarbamoylamino)acetic acid Chemical compound CCCCNC(=O)NCC(O)=O KGWHMDCQVDMTNZ-UHFFFAOYSA-N 0.000 claims description 4
- HQVZOORKDNCGCK-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-4-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(CC=2C(=CC(Cl)=CC=2)Cl)=C1 HQVZOORKDNCGCK-UHFFFAOYSA-N 0.000 claims description 4
- YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 claims description 4
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims description 4
- ODUOJXZPIYUATO-UHFFFAOYSA-N 2-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]acetic acid (phenylmethyl) ester Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 claims description 4
- RMWVZGDJPAKBDE-UHFFFAOYSA-N 2-acetyloxy-4-(trifluoromethyl)benzoic acid Chemical compound CC(=O)OC1=CC(C(F)(F)F)=CC=C1C(O)=O RMWVZGDJPAKBDE-UHFFFAOYSA-N 0.000 claims description 4
- KCVTVKMPZQSSNU-UHFFFAOYSA-N 2-pyridin-4-ylethanethioyl chloride Chemical compound ClC(=S)CC1=CC=NC=C1 KCVTVKMPZQSSNU-UHFFFAOYSA-N 0.000 claims description 4
- VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 claims description 4
- RKPHTRVPGYGVQD-UHFFFAOYSA-N 4-amino-2-hydroxybenzoic acid;pyridine-4-carbohydrazide Chemical compound NNC(=O)C1=CC=NC=C1.NC1=CC=C(C(O)=O)C(O)=C1 RKPHTRVPGYGVQD-UHFFFAOYSA-N 0.000 claims description 4
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 claims description 4
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 claims description 4
- YBJHBAHKTGYVGT-OOZYFLPDSA-N 5-[(3as,4r,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-OOZYFLPDSA-N 0.000 claims description 4
- KNWODGJQLCISLC-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 KNWODGJQLCISLC-UHFFFAOYSA-N 0.000 claims description 4
- BMACYHMTJHBPOX-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl BMACYHMTJHBPOX-UHFFFAOYSA-N 0.000 claims description 4
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 claims description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 4
- 108010001478 Bacitracin Proteins 0.000 claims description 4
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims description 4
- CWXYHOHYCJXYFQ-UHFFFAOYSA-N Betamipron Chemical compound OC(=O)CCNC(=O)C1=CC=CC=C1 CWXYHOHYCJXYFQ-UHFFFAOYSA-N 0.000 claims description 4
- HEYVINCGKDONRU-UHFFFAOYSA-N Bupropion hydrochloride Chemical compound Cl.CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 HEYVINCGKDONRU-UHFFFAOYSA-N 0.000 claims description 4
- 108010020326 Caspofungin Proteins 0.000 claims description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 4
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 4
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 4
- GTNDZRUWKHDICY-DJHAJVGHSA-N Clindamycin palmitate hydrochloride Chemical compound Cl.O1[C@H](SC)[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](O)[C@@H](O)[C@H]1[C@@H]([C@H](C)Cl)NC(=O)[C@H]1N(C)C[C@H](CCC)C1 GTNDZRUWKHDICY-DJHAJVGHSA-N 0.000 claims description 4
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 4
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 claims description 4
- 108010078777 Colistin Proteins 0.000 claims description 4
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 4
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 4
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 claims description 4
- 108010013198 Daptomycin Proteins 0.000 claims description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 4
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 claims description 4
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 4
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims description 4
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims description 4
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 claims description 4
- KMZQAVXSMUKBPD-DJWKRKHSSA-N Lafutidine Chemical compound C=1C=COC=1C[S+]([O-])CC(=O)NC\C=C/COC(N=CC=1)=CC=1CN1CCCCC1 KMZQAVXSMUKBPD-DJWKRKHSSA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4
- VPHPQNGOVQYUMG-UHFFFAOYSA-N Liranaftate Chemical compound COC1=CC=CC(N(C)C(=S)OC=2C=C3CCCCC3=CC=2)=N1 VPHPQNGOVQYUMG-UHFFFAOYSA-N 0.000 claims description 4
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 claims description 4
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 4
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 4
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 claims description 4
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 4
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims description 4
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 claims description 4
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 4
- 239000004187 Spiramycin Substances 0.000 claims description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 4
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 claims description 4
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 4
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 claims description 4
- 108010053950 Teicoplanin Proteins 0.000 claims description 4
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 claims description 4
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 claims description 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 4
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 4
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 claims description 4
- QWSHKNICRJHQCY-VBTXLZOXSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate;ethanol Chemical compound CCO.C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 QWSHKNICRJHQCY-VBTXLZOXSA-N 0.000 claims description 4
- 229960000531 abacavir sulfate Drugs 0.000 claims description 4
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 claims description 4
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 claims description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 4
- VXTGHWHFYNYFFV-UHFFFAOYSA-N albendazole S-oxide Chemical compound CCCS(=O)C1=CC=C2NC(NC(=O)OC)=NC2=C1 VXTGHWHFYNYFFV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004821 amikacin Drugs 0.000 claims description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
- 229960001656 amikacin sulfate Drugs 0.000 claims description 4
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- MQHLMHIZUIDKOO-AYHJJNSGSA-N amorolfine Chemical compound C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 claims description 4
- 229960005279 amorolfine hydrochloride Drugs 0.000 claims description 4
- 229960002793 amoxicillin sodium Drugs 0.000 claims description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 4
- 229960001931 ampicillin sodium Drugs 0.000 claims description 4
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 claims description 4
- 229960003311 ampicillin trihydrate Drugs 0.000 claims description 4
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 4
- 229940025141 anafranil Drugs 0.000 claims description 4
- SGHXFFAHXTZRQM-SPIKMXEPSA-N azatadine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SGHXFFAHXTZRQM-SPIKMXEPSA-N 0.000 claims description 4
- 229960004924 azithromycin dihydrate Drugs 0.000 claims description 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 4
- 229960003071 bacitracin Drugs 0.000 claims description 4
- 229930184125 bacitracin Natural products 0.000 claims description 4
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 4
- 229960001192 bekanamycin Drugs 0.000 claims description 4
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 claims description 4
- 229940024774 benztropine mesylate Drugs 0.000 claims description 4
- 229950007599 betamipron Drugs 0.000 claims description 4
- 229960003169 biapenem Drugs 0.000 claims description 4
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims description 4
- 229960002206 bifonazole Drugs 0.000 claims description 4
- 229940097201 bismuth subcitrate potassium Drugs 0.000 claims description 4
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 4
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000725 brompheniramine Drugs 0.000 claims description 4
- 229960002120 butoconazole nitrate Drugs 0.000 claims description 4
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 claims description 4
- 229960000427 carbadox Drugs 0.000 claims description 4
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001704 carbimazole Drugs 0.000 claims description 4
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 claims description 4
- 229960000730 caspofungin acetate Drugs 0.000 claims description 4
- 229940063628 catapres Drugs 0.000 claims description 4
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 4
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 4
- 229950001580 cefoselis Drugs 0.000 claims description 4
- LZOLCSVRFKCSEM-ZQCAECPKSA-N cefoselis sulfate Chemical compound OS(O)(=O)=O.S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO LZOLCSVRFKCSEM-ZQCAECPKSA-N 0.000 claims description 4
- 229960003547 ceftazidime pentahydrate Drugs 0.000 claims description 4
- 229960001356 ceftiofur hydrochloride Drugs 0.000 claims description 4
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 4
- VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 claims description 4
- 229940009063 cephapirin sodium Drugs 0.000 claims description 4
- 229960000800 cetrimonium bromide Drugs 0.000 claims description 4
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 4
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 4
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 4
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 4
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 4
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 4
- 229960004736 chloroxine Drugs 0.000 claims description 4
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001761 chlorpropamide Drugs 0.000 claims description 4
- 229960002172 chlorquinaldol Drugs 0.000 claims description 4
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004475 chlortetracycline Drugs 0.000 claims description 4
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 4
- 229960003749 ciclopirox Drugs 0.000 claims description 4
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004621 cinoxacin Drugs 0.000 claims description 4
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003344 climbazole Drugs 0.000 claims description 4
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 claims description 4
- 229960002227 clindamycin Drugs 0.000 claims description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 4
- 229960002291 clindamycin phosphate Drugs 0.000 claims description 4
- 229960004287 clofazimine Drugs 0.000 claims description 4
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 4
- 229960003769 clofoctol Drugs 0.000 claims description 4
- 229960001564 clomipramine hydrochloride Drugs 0.000 claims description 4
- 229960002925 clonidine hydrochloride Drugs 0.000 claims description 4
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004531 colistimethate sodium Drugs 0.000 claims description 4
- IQWHCHZFYPIVRV-VLLYEMIKSA-I colistin A sodium methanesulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].CC[C@@H](C)CCCCC(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCNCS([O-])(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS([O-])(=O)=O)NC1=O IQWHCHZFYPIVRV-VLLYEMIKSA-I 0.000 claims description 4
- 229960001127 colistin sulfate Drugs 0.000 claims description 4
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 claims description 4
- 229940066901 crestor Drugs 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 229960003850 dabigatran Drugs 0.000 claims description 4
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 4
- 229960000288 dabigatran etexilate Drugs 0.000 claims description 4
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims description 4
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 4
- 229960005484 daptomycin Drugs 0.000 claims description 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 4
- UQAVIASOPREUIT-VQIWEWKSSA-N darifenacin hydrobromide Chemical compound Br.C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 UQAVIASOPREUIT-VQIWEWKSSA-N 0.000 claims description 4
- 229960000248 diclazuril Drugs 0.000 claims description 4
- 229960004515 diclofenac potassium Drugs 0.000 claims description 4
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims description 4
- 229960004060 dicloxacillin sodium Drugs 0.000 claims description 4
- SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 claims description 4
- 229960004100 dirithromycin Drugs 0.000 claims description 4
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001859 domiphen bromide Drugs 0.000 claims description 4
- 229960000895 doripenem Drugs 0.000 claims description 4
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 4
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000740 enrofloxacin Drugs 0.000 claims description 4
- 229960000980 entecavir Drugs 0.000 claims description 4
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 4
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 claims description 4
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 claims description 4
- 229960005086 escitalopram oxalate Drugs 0.000 claims description 4
- 229960002001 ethionamide Drugs 0.000 claims description 4
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 4
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 claims description 4
- 229960000628 fidaxomicin Drugs 0.000 claims description 4
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 claims description 4
- 229960003760 florfenicol Drugs 0.000 claims description 4
- 229960004884 fluconazole Drugs 0.000 claims description 4
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 4
- 229960003923 gatifloxacin Drugs 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- DWSGTFTVBLXELC-MOTQWOLNSA-N hydron;[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide Chemical compound Br.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 DWSGTFTVBLXELC-MOTQWOLNSA-N 0.000 claims description 4
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 claims description 4
- 229960004716 idoxuridine Drugs 0.000 claims description 4
- 229960004735 indacaterol maleate Drugs 0.000 claims description 4
- IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 claims description 4
- 229960004007 isoconazole nitrate Drugs 0.000 claims description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 4
- SKKLOUVUUNMCJE-FQSMHNGLSA-N kanamycin B Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 claims description 4
- 229930182824 kanamycin B Natural products 0.000 claims description 4
- SKKLOUVUUNMCJE-UHFFFAOYSA-N kanendomycin Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)C(O)C(CO)O2)O)C(N)CC1N SKKLOUVUUNMCJE-UHFFFAOYSA-N 0.000 claims description 4
- 229960004125 ketoconazole Drugs 0.000 claims description 4
- 229960003303 lafutidine Drugs 0.000 claims description 4
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 4
- 229960000433 latamoxef Drugs 0.000 claims description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 4
- 229950010148 liranaftate Drugs 0.000 claims description 4
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 claims description 4
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 claims description 4
- 229960002983 loperamide hydrochloride Drugs 0.000 claims description 4
- 229960002531 marbofloxacin Drugs 0.000 claims description 4
- 229940103196 maxaquin Drugs 0.000 claims description 4
- 229960004737 meclocycline sulfosalicylate Drugs 0.000 claims description 4
- 229960002140 medetomidine Drugs 0.000 claims description 4
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 claims description 4
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 4
- 229960004296 megestrol acetate Drugs 0.000 claims description 4
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 4
- 229960003505 mequinol Drugs 0.000 claims description 4
- 229960002260 meropenem Drugs 0.000 claims description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 4
- ILVPFTMKCHREDJ-UHFFFAOYSA-N methyl 5-amino-2-fluorobenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1F ILVPFTMKCHREDJ-UHFFFAOYSA-N 0.000 claims description 4
- BPMVRAQIQQEBLN-OBPBNMOMSA-N methyl n-[(e)-(1-hydroxy-4-oxidoquinoxalin-4-ium-2-ylidene)methyl]iminocarbamate Chemical compound C1=CC=C2N(O)C(=C/N=NC(=O)OC)/C=[N+]([O-])C2=C1 BPMVRAQIQQEBLN-OBPBNMOMSA-N 0.000 claims description 4
- 229960002545 methylthiouracil Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001994 mezlocillin sodium Drugs 0.000 claims description 4
- 229960005040 miconazole nitrate Drugs 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims description 4
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims description 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 4
- 229940049018 mycostatin Drugs 0.000 claims description 4
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 claims description 4
- 229960004313 naftifine Drugs 0.000 claims description 4
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims description 4
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 4
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 4
- 229960004832 netilmicin sulfate Drugs 0.000 claims description 4
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000916 niflumic acid Drugs 0.000 claims description 4
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical compound C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 claims description 4
- 229960003888 nifuroxazide Drugs 0.000 claims description 4
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 4
- 229940079063 norflex Drugs 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000988 nystatin Drugs 0.000 claims description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004780 orbifloxacin Drugs 0.000 claims description 4
- 229960001687 orphenadrine citrate Drugs 0.000 claims description 4
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 4
- 229960003924 oxytetracycline dihydrate Drugs 0.000 claims description 4
- 229960005065 paromomycin sulfate Drugs 0.000 claims description 4
- 229960002296 paroxetine Drugs 0.000 claims description 4
- 229950005819 pasiniazid Drugs 0.000 claims description 4
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims description 4
- 229960001808 pefloxacin mesylate Drugs 0.000 claims description 4
- 229960001179 penciclovir Drugs 0.000 claims description 4
- 229940056360 penicillin g Drugs 0.000 claims description 4
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims description 4
- 229960004448 pentamidine Drugs 0.000 claims description 4
- 229960003893 phenacetin Drugs 0.000 claims description 4
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004444 piromidic acid Drugs 0.000 claims description 4
- 229960001589 posaconazole Drugs 0.000 claims description 4
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 4
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 claims description 4
- 229940087661 priftin Drugs 0.000 claims description 4
- 229960005179 primaquine Drugs 0.000 claims description 4
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001141 pyrithione zinc Drugs 0.000 claims description 4
- 229950004535 rebamipide Drugs 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940063639 rifadin Drugs 0.000 claims description 4
- 229960001225 rifampicin Drugs 0.000 claims description 4
- 229960002599 rifapentine Drugs 0.000 claims description 4
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims description 4
- 229940049560 rimactane Drugs 0.000 claims description 4
- 229960001634 ritodrine Drugs 0.000 claims description 4
- 229960000720 ritodrine hydrochloride Drugs 0.000 claims description 4
- 229960000311 ritonavir Drugs 0.000 claims description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 4
- 229960005009 rolitetracycline Drugs 0.000 claims description 4
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 claims description 4
- 229960001549 ropivacaine Drugs 0.000 claims description 4
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims description 4
- 229960003271 rosiglitazone maleate Drugs 0.000 claims description 4
- 229960004796 rosuvastatin calcium Drugs 0.000 claims description 4
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 claims description 4
- 229950000975 salicylanilide Drugs 0.000 claims description 4
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 4
- 229960004476 sertaconazole nitrate Drugs 0.000 claims description 4
- 229960004025 sodium salicylate Drugs 0.000 claims description 4
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims description 4
- 229960004954 sparfloxacin Drugs 0.000 claims description 4
- 229960001294 spiramycin Drugs 0.000 claims description 4
- 235000019372 spiramycin Nutrition 0.000 claims description 4
- 229930191512 spiramycin Natural products 0.000 claims description 4
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 4
- 229960002256 spironolactone Drugs 0.000 claims description 4
- 229960001203 stavudine Drugs 0.000 claims description 4
- 229960002385 streptomycin sulfate Drugs 0.000 claims description 4
- 229960004718 sulconazole nitrate Drugs 0.000 claims description 4
- 229960004306 sulfadiazine Drugs 0.000 claims description 4
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 4
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000654 sulfafurazole Drugs 0.000 claims description 4
- 229960004257 sulfaguanidine Drugs 0.000 claims description 4
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002597 sulfamerazine Drugs 0.000 claims description 4
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 claims description 4
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 claims description 4
- 229960005404 sulfamethoxazole Drugs 0.000 claims description 4
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 claims description 4
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 4
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 claims description 4
- 229960001544 sulfathiazole Drugs 0.000 claims description 4
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- 229960001608 teicoplanin Drugs 0.000 claims description 4
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 claims description 4
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 4
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims description 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 4
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims description 4
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 claims description 4
- NZMOFYDMGFQZLS-UHFFFAOYSA-N terazosin hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 NZMOFYDMGFQZLS-UHFFFAOYSA-N 0.000 claims description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 4
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims description 4
- OVICLFZZVQVVFT-UHFFFAOYSA-N tert-butyl-[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]azanium;hydrogen sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 OVICLFZZVQVVFT-UHFFFAOYSA-N 0.000 claims description 4
- 229940063214 thiostrepton Drugs 0.000 claims description 4
- 229930188070 thiostrepton Natural products 0.000 claims description 4
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 claims description 4
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 claims description 4
- 229940051002 thonzonium bromide Drugs 0.000 claims description 4
- WBWDWFZTSDZAIG-UHFFFAOYSA-M thonzonium bromide Chemical compound [Br-].N=1C=CC=NC=1N(CC[N+](C)(C)CCCCCCCCCCCCCCCC)CC1=CC=C(OC)C=C1 WBWDWFZTSDZAIG-UHFFFAOYSA-M 0.000 claims description 4
- 229960004089 tigecycline Drugs 0.000 claims description 4
- 229960000223 tilmicosin Drugs 0.000 claims description 4
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 claims description 4
- 229960005053 tinidazole Drugs 0.000 claims description 4
- 229960004214 tioconazole Drugs 0.000 claims description 4
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 claims description 4
- 229960000898 toltrazuril Drugs 0.000 claims description 4
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 claims description 4
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 4
- 229960002268 triflusal Drugs 0.000 claims description 4
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 4
- 229960001082 trimethoprim Drugs 0.000 claims description 4
- 229960000200 ulipristal Drugs 0.000 claims description 4
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims description 4
- 229960004740 voriconazole Drugs 0.000 claims description 4
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 4
- OGUJBRYAAJYXQP-IJFZAWIJSA-N vuw370o5qe Chemical compound CC(O)=O.CC(O)=O.C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 OGUJBRYAAJYXQP-IJFZAWIJSA-N 0.000 claims description 4
- 229960000833 xylometazoline Drugs 0.000 claims description 4
- 229960000523 zalcitabine Drugs 0.000 claims description 4
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 4
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 4
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 claims description 3
- FKENQMMABCRJMK-UHFFFAOYSA-N 3,3-dimethyl-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=S1(=O)C(C)(C)C(C(O)=O)N2C(=O)CC21 FKENQMMABCRJMK-UHFFFAOYSA-N 0.000 claims description 3
- JFMGBGLSDVIOHL-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 JFMGBGLSDVIOHL-UHFFFAOYSA-N 0.000 claims description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229950003476 aminothiazole Drugs 0.000 claims description 3
- 230000001165 anti-coccidial effect Effects 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 3
- 150000001491 aromatic compounds Chemical class 0.000 claims description 3
- 229960003644 aztreonam Drugs 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229960005255 carbenicillin disodium Drugs 0.000 claims description 3
- RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 claims description 3
- AZFBLLCNOQPJGJ-DVAZEERGSA-N chembl1332607 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)N2)C)OC)C(C(=C3O)C)=C1C(C1=N4)=C3C(O)=C2C1=NC14CCN(CC(C)C)CC1 AZFBLLCNOQPJGJ-DVAZEERGSA-N 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 229960002963 ganciclovir Drugs 0.000 claims description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 3
- 229960001031 glucose Drugs 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229960001907 nitrofurazone Drugs 0.000 claims description 3
- 229960000770 ondansetron hydrochloride Drugs 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229960005222 phenazone Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960000973 sulfadimethoxine Drugs 0.000 claims description 3
- 229940020930 unasyn Drugs 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229960005264 piperacillin sodium Drugs 0.000 claims description 2
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 229960004069 cefditoren Drugs 0.000 claims 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950009297 pivoxil Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 3
- 229960002142 cefditoren pivoxil Drugs 0.000 description 3
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- -1 Ganciclov Ir Chemical compound 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950001733 difloxacin Drugs 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940027817 mycobutin Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960000918 protionamide Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
本發明提供多種抗生素藥物的新臨床之應用。該多種抗生素藥物皆是經過衛生署通過核准上市的抗生素藥物。本發明提供多種抗生素藥物有效的抑制不同類型的癌細胞。
Description
本發明係為多種抗生素藥物的新適應症之應用,尤其該多種藥物為通過臨床實驗且具有抑制多種癌症之用途。
癌症長期高居全球死因之首,且罹患癌症人數更是逐年攀升,因此治療癌症儼然成為重要的課題。癌症的治療可區分為手術治療、放射線治療、化學治療及標靶治療。
一般來說,癌症藥物治療無論是化學治療或標靶治療,目的多是讓癌細胞無法複製、分裂,來阻斷腫瘤的蔓延擴張。在臨床治療選擇上,通常會結合一到數種化療藥物以及標靶治療,希望能藉由不同機制來殺死癌細胞以提高治療效果,但事實上,還是常遇到患者對於治療藥物的反應不佳。進一步,許多癌細胞相繼產生抗藥性,使藥物的使用成效大幅降低,最終導致癌症治療失敗。
抗生素(英語:antibiotic)由微生物(包括細菌、真菌、放線菌屬)所產生的具有抑制其它類微生物生長、生存的一類次級代謝產物,以及用化學方法合成或半合成的類似化合物。在
定義上是一較廣的概念,包括抗細菌抗生素、抗真菌抗生素以及對付其他微小病原之抗生素;但臨床實務中,抗生素常常是指抗細菌抗生素。
發明人依據長年的研究經驗,人類的癌症細胞常常
有與正常細胞具有不同的表現性狀,型態上的差異或是作用機轉的變化或許也有可能被視為一種外來的侵入者,而每一種癌症細胞所在的位置不同,變異的狀態又與所處的環境有關,因此,第一個提出使用抗生素藥物抑制癌症細胞的發明概念並且進行實驗。
相對的,在這些已經使用數十年抗生素,是早已被
FDA所認可的用藥,具有大量藥物機轉及人體研究成果資料,因此,若應用在癌症方面,這項新發展會更省時、減少成本,也能和其他治療方式結合來提高效果。
在發明人提出美國臨時申請案之後,亦有其他的教
授深入研究探討其可能性,近期亦陸續有相關的研究提出並證實發明人的發明內容,該教授根據內共生理論(Endosymbiotic Theory)提出相類似的假設,意即粒線體曾經是細菌,後來被大型細菌併吞後,在其細胞內與之共生,因此粒線體和一般細胞結構不太一樣,它有自己的基因,和原核生物(如細菌)比較接近。這種差異就也許就能被設計成像標靶治療一樣,單獨抑制癌症細胞的治療。
儘管如此,藥物開發依然是重要的醫學議題,必須經過繁複的臨床前試驗才能進入臨床試驗,根據統計,平均每一萬個新藥約只有五個能夠進入第一期臨床試驗。此外,除了藥物本身是否能大量製造的難題外,還需克服藥物安全性、病人篩選、試用劑量等問題,即便藥物已經通過FDA的核准並上市,亦有可能因上市後於人體發現不良反應而強制下架回收,由此可見藥物開發具有一定的困難程度。
為解決上述的問題,本發明係針對通過臨床實驗的多種藥物進行新適應症的研發,而達到老藥新用的目標。
經過實驗設計結果顯示抗生素藥物對正常細胞沒有或僅有微小的毒性,但至於抗生素在正常細胞與腫瘤細胞之間是否具有選擇性的影響,還待更多的研究釐清,而且並非所有的抗生素在相同的條件下均能有效的抑制腫瘤細胞,需要有許多的問題進行克服。
抗生素依據藥物的結構可以分為九大類,包含胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、青黴素類抗生素、紅黴素類抗生素、四環
素類抗生素,與其他類。
1. 氨基糖苷類抗生素,氨基糖苷類抗生素是具有氨基
糖與氨基環醇結構的一類抗生素,在臨床主要用於對革蘭氏陰性菌、綠膿桿菌等感染的治療。本發明中的抗生素藥物包含在本類別的有Amikacin sulfate、Amikacin hydrate、Netilmicin Sulfate。
2. 抗黴菌劑抗生素,一系列抗黴菌的抗生素。本發
明中的抗生素藥物包含在本類別的有Posaconazole、Artemisinin、Fluconazole、Ketoconazole、Voriconazole、Natamycin(Pimaricin)、Clotrimazole(Canesten)、Amphotericin B(Abelcet)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Terbinafine(Lamisil,Terbinex)、Butoconazole nitrate、Chloroxine、Bifonazole、Tioconazole、Nystatin(Mycostatin)、Miconazole nitrate、Liranaftate、Isoconazole nitrate(Travogen)、Terbinafine hydrochloride(Lamisil)、Ciclopirox ethanolamine、Caspofungin acetate、Naftifine HCl、Sertaconazole nitrate、Pyrithione zinc、Sulconazole Nitrate、Climbazole、Valnemulin HCl。
3. 頭孢子菌類抗生素,頭孢菌素,又名先鋒霉素,
是一系列屬於β內醯胺類的抗生素。與頭黴素一併細分為頭孢烯。本發明中的抗生素藥物包含在本類別的有Cefdinir(Omnicef)、
Cefoperazone(Cefobid)、Cefditoren pivoxil、Cephalexin(Cefalexin)、Cefoselis sulfate、Ceftiofur hydrochloride、Cefaclor(Ceclor)、Ceftazidime Pentahydrate、Moxalactam Disodium、Cephapirin Sodium。
4. β-丙醯胺抗生素類,β-內醯胺類抗生素(Beta-lactam antibiotic)是一種種類很廣的抗生素,其中包括青黴素及其衍生物、頭孢菌素、單醯胺環類、碳青黴烯和青黴烯類酶抑制劑等。基本上所有在其分子結構中包括β-內醯胺核的抗生素均屬於β內醯胺類抗生素。它是現有的抗生素中使用最廣泛的一類。本發明中的抗生素藥物包含在本類別的有Doripenem Hydrate、Meropenem、Aztreonam、Sulbactam、Sulbactam sodium(Unasyn)、Biapenem。
5. 氯黴素抗生素,氯黴素有著很廣泛的活躍性,能有效對抗革蘭氏陽性菌,包括大部份的抗藥性金黃色葡萄球菌、革蘭氏陰性菌及厭氧性生物。本發明中的抗生素藥物包含在本類別的有Gatifloxacin、Daptomycin、Sulfapyridine(Dagenan)、Sulfameter(Bayrena)、Chloramphenicol(Chloromycetin)。
6. 青黴素類抗生素,青黴素(Penicillin,或音譯盤尼西林)是指分子中含有青黴烷、能破壞細菌的細胞壁並在細菌細
胞的繁殖期起殺菌作用的一類抗生素,是由青黴菌中提煉出的抗生素。青黴素屬於β-內醯胺類抗生素(β-lactams),β-內醯胺類抗生素包括青黴素、頭孢菌素、碳青黴烯類、單環類、頭黴素類等。
本發明中的抗生素藥物包含在本類別的有Amoxicillin sodium(Amox)、Ampicillin sodium、Carbenicillin disodium、Dicloxacillin Sodium、Ampicillin Trihydrate、Benzylpenicillin sodium、Mezlocillin Sodium、Piperacillin Sodium。
7. 紅黴素類抗生素,紅黴素(英文:Erythromycin)是一種大環內酯類的抗生素。抗菌範圍與青黴素相似;主要用於對青黴素已經產生耐藥性的葡萄球菌、鏈球菌、腹瀉等胃腸道反應。本發明中的抗生素藥物包含在本類別的有Teicoplanin、Linezolid(Zyvox)、Erythromycin(E-Mycin)、Erythromycin Ethylsuccinate、Spiramycin、Tilmicosin、Azithromycin Dihydrate、Dirithromycin、Fidaxomicin。
8. 四環素類抗生素,一個廣效抗生素(Broad-spectrum antibiotic)藥物家族的泛稱,因其氫化並四苯母核而得名。本類藥物抗菌譜廣,對革蘭氏陰性菌、革蘭氏陽性菌、螺旋體、衣原體、立克次氏體、支原體、放線菌和阿米巴原蟲都有較強的作用。本發明中的抗生素藥物包含在本類別的有
Marbofloxacin、Moxifloxacin hydrochloride、Oxytetracycline(Terramycin)、Tigecycline、Oxytetracycline dihydrate、Tetracycline HCl、Chlortetracycline HCl、Minocycline HCl、Rolitetracycline。
9. 其他類抗生素:Norfloxacin(Norxacin)、Enoxacin
(Penetrex)、Pefloxacin mesylate、Sparfloxacin、Levofloxacin(Levaquin)、Sarafloxacin HCl、Nalidixic acid(NegGram)、Lomefloxacin hydrochloride(Maxaquin)、Enrofloxacin、Clinafloxacin(PD127391)、Orbifloxacin、Clinafoxacin HCl、Piromidic Acid、Cinoxacin、Difloxacin HC、Rifabutin(Mycobutin)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Ethionamide、Rifaximin(Xifaxan)、Protionamide(Prothionamide)、Isoniazid(Tubizid)、D-Cycloserine、Streptomycin sulfate、Clofazimine、Nitrofurazone、Sulfanilamide、Sulfadiazine、Metronidazole(Flagyl)、Sulfamethoxazole、Sulfisoxazole、Sulfamethizole(Proklar)、Sulfadimethoxine、Clindamycin phosphate、Fenbendazole(Panacur)、Sulfadoxine(Sulphadoxine)、Secnidazole(Flagentyl)、Clindamycin palmitate HCl、Clindamycin、Sulfathiazole、Trimethoprim、Sulfamerazine、Pentamidine、Colistin Sulfate(polypeptide)、toltrazuril、tinidazoleMequinol、Bacitracin、
Cetylpyridinium Chloride、Sulfaguanidine、Paromomycin Sulfate、Domiphen Bromide、Chlorquinaldol、Furaltadone HCl、Primaquine Diphosphate、Carbadox、Colistimethate Sodium、Meclocycline Sulfosalicylate、Thiostrepton、Bekanamycin、Clofoctol、Ritonavir、Entecavir hydrate、Artemisinin、Megestrol Acetate、Lansoprazole、Lopinavir(ABT-378)、Ondansetron hydrochloride、Resveratrol、Stavudine、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Cidofovir(Vistide)、Telaprevir(VX-950)、Saxagliptin(BMS-477118,Onglyza)、Darunavir Ethanolate(Prezista)、Docosanol(Abreva)、Amprenavir(Agenerase)、Telbivudine(Sebivo,Tyzeka)、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Prednisolone(Hydroretrocortine)、Nevirapine(Viramune)、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Acyclovir(Aciclovir)、Albendazole Oxide(Ricobendazole)、Chenodeoxycholic acid、Valaciclovir HCl、Ganciclovir、Idoxuridine、Crystal violet、Rimantadine(Flumadine)、Taurine(organic acid)、Diclazuril(anticoccidial drug)、Rebamipide、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose、BIBR-1048
(Dabigatran)、Rosuvastatin calcium(Crestor)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Tenoxicam(Mobiflex)、Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride(Anafranil)、Tiotropium Bromide hydrate、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Medetomidine HCl、Diclofenac Potassium、Ulipristal、Indacaterol Maleate、Biotin(Vitamin B7)、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Benztropine mesylate、Abacavir sulfate、Antipyrine、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Carbimazole、Spironolactone、Ropivacaine HCl、Escitalopram oxalate、Bismuth Subcitrate Potassium(mineral)、
Chlorpropamide、Nifuroxazide、Penciclovir、Salicylanilide、Betamipron、Ethacridine lactate monohydrate(aromatic compound)、Aminothiazole、Florfenicol、Cetrimonium Bromide(antiseptic)、Thonzonium Bromide(detergent)、Pasiniazid。
本發明提供一種抗生素藥物用於製備治療癌症之用途,其中該醫藥組合物係選自由一有效劑量的一抗生素及一藥物可接受的鹽類所組成。
本發明提供一種抗病毒藥物用於製備治療癌症之用途,其中該醫藥組合物係選自由一有效劑量的一抗病毒藥物及一藥物可接受的鹽類所組成。
本發明所述之抗生素係選自由胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、紅黴素類抗生素、青黴素類抗生素、四環素類抗生素及其他抗生素所組成群組之抗生素。
本發明一實施例中,其中該胺基配糖體抗生素係選自由Amikacin sulfate、Amikacin hydrate、Netilmicin Sulfate所組成之藥物。
本發明一實施例中,其中該抗黴菌劑抗生素係選自由Posaconazole、Artemisinin、Fluconazole、Ketoconazole、
Voriconazole、Natamycin(Pimaricin)、Clotrimazole(Canesten)、Amphotericin B(Abelcet)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Terbinafine(Lamisil,Terbinex)、Butoconazole nitrate、Chloroxine、Bifonazole、Tioconazole、Nystatin(Mycostatin)、Miconazole nitrate、Liranaftate、Isoconazole nitrate(Travogen)、Terbinafine hydrochloride(Lamisil)、Ciclopirox ethanolamine、Caspofungin acetate、Naftifine HCl、Sertaconazole nitrate、Pyrithione zinc、Sulconazole Nitrate、Climbazole、Valnemulin HCl所組成之藥物。
本發明一實施例中,其中頭孢子菌類抗生素係選自
由Cefdinir(Omnicef)、Cefoperazone(Cefobid)、Cefditoren pivoxil、Cephalexin(Cefalexin)、Cefoselis sulfate、Ceftiofur hydrochloride、Cefaclor(Ceclor)、Ceftazidime Pentahydrate、Moxalactam Disodium、Cephapirin Sodium所組成之藥物。
本發明一實施例中,其中β-丙醯胺抗生素係選自由
Doripenem Hydrate、Meropenem、Aztreonam、Sulbactam、Sulbactam sodium(Unasyn)、Biapenem所組成之藥物。
本發明一實施例中,其中該氯黴素抗生素係選自由
Gatifloxacin、Daptomycin、Sulfapyridine(Dagenan)、Sulfameter
(Bayrena)、Chloramphenicol(Chloromycetin)所組成之藥物。
本發明一實施例中,其中該青黴素類抗生素係選自
由Amoxicillin sodium(Amox)、Ampicillin sodium、Carbenicillin disodium、Dicloxacillin Sodium、Ampicillin Trihydrate、Benzylpenicillin sodium、Mezlocillin Sodium、Piperacillin Sodium所組成之藥物。
本發明一實施例中,其中該紅黴素類抗生素係選自
由Teicoplanin、Linezolid(Zyvox)、Erythromycin(E-Mycin)、Erythromycin Ethylsuccinate、Spiramycin、Tilmicosin、Azithromycin Dihydrate、Dirithromycin、Fidaxomicin所組成之藥物。
本發明一實施例中,其中該四環素類抗生素係選自
由Marbofloxacin、Moxifloxacin hydrochloride、Oxytetracycline(Terramycin)、Tigecycline、Oxytetracycline dihydrate、Tetracycline HCl、Chlortetracycline HCl、Minocycline HCl、Rolitetracycline。所組成之藥物。
本發明一實施例中,其中該其他抗生素係選自由
Norfloxacin(Norxacin)、Enoxacin(Penetrex)、Pefloxacin mesylate、Sparfloxacin、Levofloxacin(Levaquin)、Sarafloxacin HCl、Nalidixic acid(NegGram)、Lomefloxacin hydrochloride(Maxaquin)、
Enrofloxacin、Clinafloxacin(PD127391)、Orbifloxacin、Clinafoxacin HCl、Piromidic Acid、Cinoxacin、Difloxacin HCl、ifabutin(Mycobutin)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Ethionamide、Rifaximin(Xifaxan)、Protionamide(Prothionamide)、Isoniazid(Tubizid)、D-Cycloserine、Streptomycin sulfate、Clofazimine、Nitrofurazone、Sulfanilamide、Sulfadiazine、Metronidazole(Flagyl)、Sulfamethoxazole、Sulfisoxazole、Sulfamethizole(Proklar)、Sulfadimethoxine、Clindamycin phosphate、Fenbendazole(Panacur)、Sulfadoxine(Sulphadoxine)、Secnidazole(Flagentyl)、Clindamycin palmitate HCl、Clindamycin、Sulfathiazole、Trimethoprim、Sulfamerazine、Pentamidine、Colistin Sulfate(polypeptide)、toltrazuril、tinidazoleMequinol、Bacitracin、Cetylpyridinium Chloride、Sulfaguanidine、Paromomycin Sulfate、Domiphen Bromide、Chlorquinaldol、Furaltadone HCl、Primaquine Diphosphate、Carbadox、Colistimethate Sodium、Meclocycline Sulfosalicylate、Thiostrepton、Bekanamycin、Clofoctol、Ritonavir、Entecavir hydrate、Artemisinin、Megestrol Acetate、Lansoprazole、Lopinavir(ABT-378)、Ondansetron hydrochloride、Resveratrol、
Stavudine、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Cidofovir(Vistide)、Telaprevir(VX-950)、Saxagliptin(BMS-477118,Onglyza)、Darunavir Ethanolate(Prezista)、Docosanol(Abreva)、Amprenavir(Agenerase)、Telbivudine(Sebivo,Tyzeka)、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Prednisolone(Hydroretrocortine)、Nevirapine(Viramune)、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Acyclovir(Aciclovir)、Albendazole Oxide(Ricobendazole)、Chenodeoxycholic acid、Valaciclovir HCl、Ganciclovir、Idoxuridine、Crystal violet、Rimantadine(Flumadine)、Taurine(organic acid)、Diclazuril(anticoccidial drug)、Rebamipide、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose、BIBR-1048(Dabigatran)、Rosuvastatin calcium(Crestor)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Tenoxicam(Mobiflex)、
Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride(Anafranil)、Tiotropium Bromide hydrate、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Medetomidine HCl、Diclofenac Potassium、Ulipristal、Indacaterol Maleate、Biotin(Vitamin B7)、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Benztropine mesylate、Abacavir sulfate、Antipyrine、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Carbimazole、Spironolactone、Ropivacaine HCl、Escitalopram oxalate、Bismuth Subcitrate Potassium(mineral)、Chlorpropamide、Nifuroxazide、Penciclovir、Salicylanilide、Betamipron、Ethacridine lactate monohydrate(aromatic compound)、Aminothiazole、Florfenicol、Cetrimonium Bromide(antiseptic)、Thonzonium Bromide(detergent)、Pasiniazid所組成之藥物。
本發明一實施例中,其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、膀胱癌、子宮頸癌、乳癌及血癌所
組成之群組。
本發明一實施例中,其中該藥物的有效劑量濃度為20mg/kg/day。
現今癌症藥物費用動輒上萬至數百萬元,若未來更進一步證實抗生素對腫瘤的療效,對於無法負擔昂貴治療的患者們,這些便宜而歷史悠久的藥物,會是帶來健康的新希望。
第一圖顯示本發明抗生素用藥應用於抑制癌細胞分析結果
請參考表一,將不同癌症類型的細胞株進行繼代培養,計算細胞數目後,回種2*106細胞數,然後加入培養該細胞株之培養液補至體積為10ml,繼續培養2-3天。之後將細胞計數,並分裝至96孔盤,其中每孔的細胞數目固定為3000顆,且體積為100ul。
細胞存活分析方法
將96孔盤中原有的培養液吸掉,每孔加入濃度10um、體積100ul的市售藥物,放置72小時後,每孔再加入100ul已稀釋的WST-1試劑,該稀釋比例為培養液與WST-1原液的體積比為9:1,最後每個孔盤的總體積為200ul,然後將96孔盤放置於37度30~90分鐘,利用elisa reader於OD450偵測吸光值,並計算各癌症細胞株之存活率。
抗生素用藥應用於抑制癌細胞分析結果
依據細胞存活分析方法針對取得的九大類抗生素藥物,包含胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、青黴素類抗生素、紅黴素類抗生素、四環素類抗生素,以及抗病毒類藥物進行測試抑制癌細胞生長的效果。
實驗結果明顯的顯示有許多的抗生素並無法有效的抑制癌症的細胞的生長(表二)。
而相對的各種的抗生素藥物分子對於各種癌症細胞
的抑制效果也不盡相同(圖一),經過發明人實驗結果,證實抗生素藥物藥物Ritonavir、Entecavir hydrate、Posaconazole、Artemisinin、Megestrol Acetate、Fluconazole、Gatifloxacin、Ketoconazole、Lansoprazole、Acitretin、Biapenem、Cefoselis sulfate、Daptomycin、Doripenem Hydrate、Lopinavir(ABT-378)、Meropenem、Ondansetron hydrochloride(Zofran)、Resveratrol、Stavudine、Teicoplanin、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Tigecycline、Linezolid(Zyvox)、Voriconazole、Marbofloxacin、Moxifloxacin hydrochloride、Cefaclor(Ceclor)、Cephalexin(Cefalexin)、Aztreonam(Azactam,Cayston)、Norfloxacin(Norxacin)、Cidofovir(Vistide)、Natamycin(Pimaricin)、Telaprevir(VX-950)、Saxagliptin
(BMS-477118,Onglyza)、Cefdinir(Omnicef)、Clotrimazole(Canesten)、Cefoperazone(Cefobid)、Sulfapyridine(Dagenan)、Sulfameter(Bayrena)、Darunavir Ethanolate(Prezista)、Erythromycin(E-Mycin)、Amphotericin B(Abelcet)、Docosanol(Abreva)、Amprenavir(Agenerase)、Nitrofurazone(Nitrofural)、Telbivudine(Sebivo,Tyzeka)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Chloramphenicol(Chloromycetin)、Sulfanilamide、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Terbinafine(Lamisil,Terbinex)、Prednisolone(Hydroretrocortine)、Rifabutin(Mycobutin)、Nevirapine(Viramune)、Enoxacin(Penetrex)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Cefditoren pivoxil、Sulfadiazine、Oxytetracycline(Terramycin)、Ethionamide、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Rifaximin(Xifaxan)、Acyclovir(Aciclovir)、Butoconazole nitrate、Albendazole Oxide(Ricobendazole)、Chloroxine、Chenodeoxycholic acid、Bifonazole、Pefloxacin mesylate、Valaciclovir HCl、Ganciclovir、Protionamide
(Prothionamide)、Idoxuridine、Sparfloxacin、Metronidazole(Flagyl)、Tioconazole、Sulfamethoxazole、Sulfisoxazole、Crystal violet、Nystatin(Mycostatin)、Isoniazid(Tubizid)、Levofloxacin(Levaquin)、Miconazole nitrate、Sulfamethizole(Proklar)、Sulbactam、Sulphadimethoxine、Rimantadine(Flumadine)、Sarafloxacin HCl、Liranaftate、D-Cycloserine、Taurine、Diclazuril、Rebamipide、Clindamycin phosphate、Oxytetracycline dihydrate、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose(D-glucose)、BIBR-1048(Dabigatran)、Rosuvastatin calcium(Crestor)、Nalidixic acid(NegGram)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fenbendazole(Panacur)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Sulfadoxine(Sulphadoxine)、Tenoxicam(Mobiflex)、Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Isoconazole nitrate(Travogen)、Secnidazole(Flagentyl)、
Lomefloxacin hydrochloride(Maxaquin)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride(Anafranil)、Ceftiofur hydrochloride、Tiotropium Bromide hydrate、Sulbactam sodium(Unasyn)、Terbinafine hydrochloride(Lamisil)、Amoxicillin sodium(Amox)、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Streptomycin sulfate、Tetracycline HCl、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Clindamycin palmitate HCl、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Clindamycin、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Ciclopirox ethanolamine、Enrofloxacin、Medetomidine HCl、Diclofenac Potassium、Amikacin sulfate、Caspofungin acetate、Ulipristal、Indacaterol Maleate、Sulfathiazole、Amikacin hydrate、Trimethoprim、Biotin(Vitamin B7)、Sulfamerazine、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Naftifine HCl、Sertaconazole nitrate、Benztropine mesylate、Abacavir sulfate、Ampicillin sodium、Antipyrine、Carbenicillin disodium、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Clinafloxacin(PD127391)、Pentamidine、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Colistin Sulfate、toltrazuril、
Carbimazole、Netilmicin Sulfate、Spironolactone、Ropivacaine HCl、Erythromycin Ethylsuccinate、Escitalopram oxalate、tinidazole、Pyrithione zinc、Mequinol、Spiramycin、Bismuth Subcitrate Potassium、Clofazimine、Dicloxacillin Sodium、Sulconazole Nitrate、Tilmicosin、Bacitracin、Azithromycin Dihydrate、Ampicillin Trihydrate、Orbifloxacin、Chlortetracycline HCl、Benzylpenicillin sodium、Chlorpropamide、Cetylpyridinium Chloride、Sulfaguanidine、Climbazole、Mezlocillin Sodium、Nifuroxazide、Paromomycin Sulfate、Penciclovir、Domiphen Bromide、Salicylanilide、Betamipron、Chlorquinaldol、Ethacridine lactate monohydrate、Aminothiazole、Florfenicol、Furaltadone HCl、Dirithromycin、Valnemulin HCl、Piperacillin Sodium、Minocycline HCl、Fidaxomicin、Primaquine Diphosphate、Cetrimonium Bromide、Carbadox、Ceftazidime Pentahydrate、Clinafoxacin HCl、Colistimethate Sodium、Meclocycline Sulfosalicylate、Moxalactam Disodium、Piromidic Acid、Rolitetracycline、Thiostrepton、Thonzonium Bromide、Cinoxacin、Bekanamycin、Difloxacin HCl、Cephapirin Sodium、Clofoctol、Pasiniazid等藥物對於不同的癌症細胞有明顯的抑制效果。(表三)
上列詳細說明係針對本發明之一可行實施例之具體說明,惟該實施例並非用以限制本發明之專利範圍,凡未脫離本發明技藝精神所為之等效實施或變更,均應包含於本發明之專利範圍中。
依據表三所示結果,針對對癌症細胞株有效之藥物進行重覆性實驗,其結果如表四所示。
表四、具抑制癌症細胞株之抗生素
Claims (12)
- 一種抗生素藥物用於製備治療癌症之用途,其中該醫藥組合物係選自由一有效劑量的一抗生素及一藥物可接受的鹽類所組成。
- 如申請專利範圍第1項所述之用途,其中該抗生素係選自由胺基配糖體抗生素、抗黴菌劑抗生素、頭孢子菌類抗生素、β-丙醯胺抗生素類、氯黴素抗生素、紅黴素類抗生素、青黴素類抗生素、四環素類抗生素及其他抗生素所組成群組之抗生素。
- 如申請專利範圍第2項所述之用途,其中該胺基配糖體抗生素係選自由Amikacin sulfate、Amikacin hydrate、Netilmicin Sulfate所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中該抗黴菌劑抗生素係選自由Posaconazole、Artemisinin、Fluconazole、Ketoconazole、Voriconazole、Natamycin(Pimaricin)、Clotrimazole(Canesten)、Amphotericin B(Abelcet)、Flucytosine(Ancobon)、Amorolfine Hydrochloride、Terbinafine(Lamisil,Terbinex)、Butoconazole nitrate、Chloroxine、Bifonazole、Tioconazole、Nystatin(Mycostatin)、Miconazole nitrate、Liranaftate、Isoconazole nitrate(Travogen)、Terbinafine hydrochloride(Lamisil)、Ciclopirox ethanolamine、Caspofungin acetate、Naftifine HCl、Sertaconazole nitrate、Pyrithione zinc、Sulconazole Nitrate、Climbazole、Valnemulin HCl所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中頭孢子菌類抗生素係選自由Cefdinir(Omnicef)、Cefoperazone(Cefobid)、Cefditoren pivoxil、Cephalexin(Cefalexin)、Cefoselis sulfate、Ceftiofur hydrochloride、Cefaclor(Ceclor)、Ceftazidime Pentahydrate、Moxalactam Disodium、Cephapirin Sodium所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中β-丙醯胺抗生素係選自由Doripenem Hydrate、Meropenem、Aztreonam、Sulbactam、Sulbactam sodium(Unasyn)、Biapenem所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中該氯黴素抗生素係選自由Gatifloxacin、Daptomycin、Sulfapyridine(Dagenan)、Sulfameter(Bayrena)、Chloramphenicol(Chloromycetin)所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中該青黴素類抗生素係選自由Amoxicillin sodium(Amox)、Ampicillin sodium、Carbenicillin disodium、Dicloxacillin Sodium、Ampicillin Trihydrate、Benzylpenicillin sodium、Mezlocillin Sodium、Piperacillin Sodium所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中該紅黴素類抗生素係選自由Teicoplanin、Linezolid(Zyvox)、Erythromycin(E-Mycin)、Erythromycin Ethylsuccinate、Spiramycin、Tilmicosin、Azithromycin Dihydrate、Dirithromycin、Fidaxomicin所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中該四環素類抗生素係選自由Marbofloxacin、Moxifloxacin hydrochloride、Oxytetracycline(Terramycin)、Tigecycline、Oxytetracycline dihydrate、Tetracycline HCl、Chlortetracycline HCl、Minocycline HCl、Rolitetracycline所組成之藥物。
- 如申請專利範圍第2項所述之用途,其中該其他抗生素係選自由Norfloxacin(Norxacin)、Enoxacin(Penetrex)、Pefloxacin mesylate、Sparfloxacin、Levofloxacin(Levaquin)、Sarafloxacin HCl、Nalidixic acid(NegGram)、Lomefloxacin hydrochloride(Maxaquin)、Enrofloxacin、Clinafloxacin(PD127391)、Orbifloxacin、Clinafoxacin HCl、Piromidic Acid、Cinoxacin、Difloxacin HCl、Rifabutin(Mycobutin)、Rifapentine(Priftin)、Pyrazinamide(Pyrazinoic acid amide)、Rifampin(Rifadin,Rimactane)、Ethionamide、Rifaximin(Xifaxan)、Protionamide(Prothionamide)、Isoniazid(Tubizid)、D-Cycloserine、Streptomycin sulfate、Clofazimine、Nitrofurazone、Sulfanilamide、Sulfadiazine、Metronidazole(Flagyl)、Sulfamethoxazole、Sulfisoxazole、Sulfamethizole(Proklar)、Sulfadimethoxine、Clindamycin phosphate、Fenbendazole(Panacur)、Sulfadoxine(Sulphadoxine)、Secnidazole(Flagentyl)、Clindamycin palmitate HCl、Clindamycin、Sulfathiazole、Trimethoprim、Sulfamerazine、Pentamidine、Colistin Sulfate(polypeptide)、toltrazuril、tinidazoleMequinol、Bacitracin、Cetylpyridinium Chloride、Sulfaguanidine、Paromomycin Sulfate、Domiphen Bromide、Chlorquinaldol、Furaltadone HCl、Primaquine Diphosphate、Carbadox、Colistimethate Sodium、Meclocycline Sulfosalicylate、Thiostrepton、Bekanamycin、Clofoctol、Ritonavir、Entecavir hydrate、Artemisinin、Megestrol Acetate、Lansoprazole、Lopinavir(ABT-378)、Ondansetron hydrochloride、Resveratrol、Stavudine、Tenofovir Disoproxil Fumarate、Tenofovir(Viread)、Cidofovir(Vistide)、Telaprevir(VX-950)、Saxagliptin(BMS-477118,Onglyza)、Darunavir Ethanolate(Prezista)、Docosanol(Abreva)、Amprenavir(Agenerase)、Telbivudine(Sebivo,Tyzeka)、Hydrocortisone(Cortisol)、Didanosine(Videx)、Emtricitabine(Emtriva)、Lamivudine(Epivir)、Adefovir Dipivoxil(Preveon,Hepsera)、Zalcitabine、Prednisolone(Hydroretrocortine)、Nevirapine(Viramune)、Trifluridine(Viroptic)、Vidarabine(Vira-A)、Acyclovir(Aciclovir)、Albendazole Oxide(Ricobendazole)、Chenodeoxycholic acid、Valaciclovir HCl、Ganciclovir、Idoxuridine、Crystal violet、Rimantadine(Flumadine)、Taurine(organic acid)、Diclazuril(anticoccidial drug)、Rebamipide、Orphenadrine citrate(Norflex)、Terazosin HCl(Hytrin)、Lafutidine、Dextrose、BIBR-1048(Dabigatran)、Rosuvastatin calcium(Crestor)、Ammonium Glycyrrhizinate(AMGZ)、Amfebutamone(Bupropion)、Clonidine hydrochloride(Catapres)、Fluocinolone acetonide(Flucort-N)、Loperamide hydrochloride、Mycophenolic(Mycophenolate)、Olanzapine(Zyprexa)、Racecadotril(Acetorphan)、Rosiglitazone maleate、Salbutamol sulfate(Albuterol)、Tenoxicam(Mobiflex)、Vardenafil(Vivanza)、Dopamine hydrochloride(Inotropin)、Ritodrine hydrochloride(Yutopar)、Riboflavin(Vitamin B2)、Clomipramine hydrochloride (Anafranil)、Tiotropium Bromide hydrate、Isoprenaline hydrochloride、Medroxyprogesterone acetate、Xylometazoline HCl、Phenacetin、Trazodone hydrochloride(Desyrel)、Brompheniramine、Acemetacin(Emflex)、Dabrafenib(GSK2118436)、Paroxetine HCl、Zanamivir(Relenza)、Niflumic acid、Medetomidine HCl、Diclofenac Potassium、Ulipristal、Indacaterol Maleate、Biotin(Vitamin B7)、Sodium salicylate、Methylthiouracil、Darifenacin HBr、Benztropine mesylate、Abacavir sulfate、Antipyrine、Amitriptyline HCl、Azatadine dimaleate、Triflusal、Pemirolast(BMY 26517)potassium、Homatropine Bromide、Carbimazole、Spironolactone、Ropivacaine HCl、Escitalopram oxalate、Bismuth Subcitrate Potassium(mineral)、Chlorpropamide、Nifuroxazide、Penciclovir、Salicylanilide、Betamipron、Ethacridine lactate monohydrate(aromatic compound)、Aminothiazole、Florfenicol、Cetrimonium Bromide(antiseptic)、Thonzonium Bromide(detergent)、Pasiniazid所組成之藥物。
- 如申請專利範圍第1項所述之用途,其中該癌症係選自由肺癌、腸道癌、大腸直腸癌、前列腺癌、膀胱癌、子宮頸癌、乳癌及血癌所組成之群組。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068298P | 2014-10-24 | 2014-10-24 | |
US62/068,298 | 2014-10-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201615217A true TW201615217A (zh) | 2016-05-01 |
TWI672150B TWI672150B (zh) | 2019-09-21 |
Family
ID=55760314
Family Applications (21)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104134963A TW201615224A (zh) | 2014-10-24 | 2015-10-23 | 消化系統疾病用藥臨床新應用 |
TW104134936A TWI621434B (zh) | 2014-10-24 | 2015-10-23 | 千憂解藥物應用於癌症治療 |
TW104134942A TW201615195A (zh) | 2014-10-24 | 2015-10-23 | 阿那格雷藥物應用於癌症治療 |
TW104134956A TW201615196A (zh) | 2014-10-24 | 2015-10-23 | 山喜多藥物應用於癌症治療 |
TW104134924A TW201615218A (zh) | 2014-10-24 | 2015-10-23 | 心血管疾病藥物臨床新應用 |
TW104134959A TW201615223A (zh) | 2014-10-24 | 2015-10-23 | 驅蟲藥臨床新應用 |
TW104134960A TW201615191A (zh) | 2014-10-24 | 2015-10-23 | 氨氯地平藥物應用於癌症治療 |
TW104134944A TW201615219A (zh) | 2014-10-24 | 2015-10-23 | 呼吸系統疾病用藥臨床新應用 |
TW104134950A TWI663969B (zh) | 2014-10-24 | 2015-10-23 | 莫諾苯宗藥物應用於癌症治療 |
TW104134946A TWI663984B (zh) | 2014-10-24 | 2015-10-23 | 神經疾病用藥臨床新應用 |
TW104134961A TW201615193A (zh) | 2014-10-24 | 2015-10-23 | 帕羅西汀藥物應用於癌症治療 |
TW104134940A TW201615186A (zh) | 2014-10-24 | 2015-10-23 | 脫克鈣藥物應用於癌症治療 |
TW104134908A TWI672150B (zh) | 2014-10-24 | 2015-10-23 | 抗生素藥物臨床新應用 |
TW104134964A TW201615225A (zh) | 2014-10-24 | 2015-10-23 | 內分泌疾病用藥臨床新應用 |
TW104134952A TW201615221A (zh) | 2014-10-24 | 2015-10-23 | 炎症用藥臨床新應用 |
TW104134933A TWI652060B (zh) | 2014-10-24 | 2015-10-23 | 阿折地平藥物應用於癌症治療 |
TW104134966A TW201615194A (zh) | 2014-10-24 | 2015-10-23 | 氨苯蝶啶藥物應用於癌症治療 |
TW104134928A TW201615197A (zh) | 2014-10-24 | 2015-10-23 | 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療 |
TW104134945A TW201615188A (zh) | 2014-10-24 | 2015-10-23 | 奈必洛爾藥物應用於癌症治療 |
TW104134965A TW201615226A (zh) | 2014-10-24 | 2015-10-23 | 代謝性疾病藥物臨床新應用 |
TW104134954A TW201615222A (zh) | 2014-10-24 | 2015-10-23 | 免疫疾病用藥臨床新應用 |
Family Applications Before (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104134963A TW201615224A (zh) | 2014-10-24 | 2015-10-23 | 消化系統疾病用藥臨床新應用 |
TW104134936A TWI621434B (zh) | 2014-10-24 | 2015-10-23 | 千憂解藥物應用於癌症治療 |
TW104134942A TW201615195A (zh) | 2014-10-24 | 2015-10-23 | 阿那格雷藥物應用於癌症治療 |
TW104134956A TW201615196A (zh) | 2014-10-24 | 2015-10-23 | 山喜多藥物應用於癌症治療 |
TW104134924A TW201615218A (zh) | 2014-10-24 | 2015-10-23 | 心血管疾病藥物臨床新應用 |
TW104134959A TW201615223A (zh) | 2014-10-24 | 2015-10-23 | 驅蟲藥臨床新應用 |
TW104134960A TW201615191A (zh) | 2014-10-24 | 2015-10-23 | 氨氯地平藥物應用於癌症治療 |
TW104134944A TW201615219A (zh) | 2014-10-24 | 2015-10-23 | 呼吸系統疾病用藥臨床新應用 |
TW104134950A TWI663969B (zh) | 2014-10-24 | 2015-10-23 | 莫諾苯宗藥物應用於癌症治療 |
TW104134946A TWI663984B (zh) | 2014-10-24 | 2015-10-23 | 神經疾病用藥臨床新應用 |
TW104134961A TW201615193A (zh) | 2014-10-24 | 2015-10-23 | 帕羅西汀藥物應用於癌症治療 |
TW104134940A TW201615186A (zh) | 2014-10-24 | 2015-10-23 | 脫克鈣藥物應用於癌症治療 |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104134964A TW201615225A (zh) | 2014-10-24 | 2015-10-23 | 內分泌疾病用藥臨床新應用 |
TW104134952A TW201615221A (zh) | 2014-10-24 | 2015-10-23 | 炎症用藥臨床新應用 |
TW104134933A TWI652060B (zh) | 2014-10-24 | 2015-10-23 | 阿折地平藥物應用於癌症治療 |
TW104134966A TW201615194A (zh) | 2014-10-24 | 2015-10-23 | 氨苯蝶啶藥物應用於癌症治療 |
TW104134928A TW201615197A (zh) | 2014-10-24 | 2015-10-23 | 蘋果酸丙氯陪拉辛錠藥物應用於癌症治療 |
TW104134945A TW201615188A (zh) | 2014-10-24 | 2015-10-23 | 奈必洛爾藥物應用於癌症治療 |
TW104134965A TW201615226A (zh) | 2014-10-24 | 2015-10-23 | 代謝性疾病藥物臨床新應用 |
TW104134954A TW201615222A (zh) | 2014-10-24 | 2015-10-23 | 免疫疾病用藥臨床新應用 |
Country Status (9)
Country | Link |
---|---|
US (7) | US20170312260A1 (zh) |
EP (3) | EP3210604B1 (zh) |
JP (1) | JP6539345B2 (zh) |
KR (1) | KR102490334B1 (zh) |
CN (3) | CN107106550A (zh) |
AU (2) | AU2015335375B2 (zh) |
ES (2) | ES2973279T3 (zh) |
TW (21) | TW201615224A (zh) |
WO (21) | WO2016062277A1 (zh) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
WO2016062277A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 驱虫药用于制备抗癌医药组合物中的应用 |
EP3236967B1 (en) | 2014-12-22 | 2019-10-16 | SUDA Pharmaceuticals Ltd | Prevention and treatment of metastatic disease in thrombocytotic cancer patients |
WO2017116049A1 (ko) * | 2015-12-31 | 2017-07-06 | 경북대학교 산학협력단 | 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물 |
EP3241562A1 (en) * | 2016-05-02 | 2017-11-08 | Fundació Institut Mar d'Investigacio Medica | Zonisamide for use in the treatment of breast cancer |
CN106074474A (zh) * | 2016-06-15 | 2016-11-09 | 中南大学湘雅医院 | 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用 |
WO2018072135A1 (zh) * | 2016-10-19 | 2018-04-26 | 微菌方舟生物科技股份有限公司 | 二氢吡啶类钙拮抗剂用于治疗癌症的用途 |
CN108066345A (zh) * | 2016-11-14 | 2018-05-25 | 武汉华杰世纪生物医药有限公司 | 一种具有抗肿瘤作用的化合物 |
KR102614709B1 (ko) | 2016-12-20 | 2023-12-18 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템 |
PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
US20200179404A1 (en) * | 2017-06-09 | 2020-06-11 | Regents Of The University Of Minnesota | Skin care formulations and skin cancer treatment |
EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
US20200129492A1 (en) * | 2017-07-03 | 2020-04-30 | Menri Group Ltd. | Treatment of cancer with dihydropyridines |
JP2019064976A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
KR101933805B1 (ko) | 2017-10-17 | 2018-12-28 | 성균관대학교산학협력단 | 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물 |
CN108186652A (zh) * | 2017-12-28 | 2018-06-22 | 深圳大学 | 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用 |
CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
US11931366B2 (en) * | 2018-04-19 | 2024-03-19 | Washington University | Compositions and methods of use thereof for treatment of proteinopathies |
CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
FR3090084B1 (fr) | 2018-12-18 | 2023-10-13 | Securengy | Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent. |
WO2020132253A1 (en) * | 2018-12-19 | 2020-06-25 | University Of Vermont And State Agricultural College | Cancer therapeutic compositions and methods |
EP3949959A4 (en) * | 2019-04-04 | 2022-05-11 | Daegu-Gyeongbuk Medical Innovation Foundation | PHARMACEUTICAL COMPOSITION COMPRISING TRIMEBUTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USED AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER |
US20220202771A1 (en) * | 2019-04-05 | 2022-06-30 | University Of North Texas Health Science Center At Fort Worth | Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging |
US20220146492A1 (en) * | 2019-04-11 | 2022-05-12 | Ian Basil Shine | Cell membrane permeability restoring therapy |
CN110179803A (zh) * | 2019-05-31 | 2019-08-30 | 天津科技大学 | 一种噻吨溴类化合物的应用 |
CN110742890A (zh) * | 2019-10-24 | 2020-02-04 | 暨南大学 | 洛美利嗪在制备抗结肠癌药物中的应用 |
CN110876800B (zh) * | 2019-11-18 | 2023-06-27 | 中南大学 | 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN110840887A (zh) * | 2019-11-18 | 2020-02-28 | 杭州彗搏科技有限公司 | 三氯苯达唑在制备治疗乳腺癌的药物中的应用 |
CN111067899B (zh) * | 2020-01-08 | 2021-03-05 | 温州医科大学 | 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用 |
US11304969B2 (en) * | 2020-01-24 | 2022-04-19 | The Florida International Univeristy Board Of Trustees | Treatments of prostate cancer |
CN111973593A (zh) * | 2020-05-09 | 2020-11-24 | 深圳市罗湖区人民医院 | 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途 |
CN111557941A (zh) * | 2020-06-15 | 2020-08-21 | 浙江大学 | Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用 |
CN111848717A (zh) * | 2020-08-07 | 2020-10-30 | 四川大学 | 靶向调控线粒体能量代谢的化合物及其应用和药物 |
TW202214244A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 具有協同抗癌功效之氯硝柳胺(Niclosamide)和雙硫侖(Disulfiram)醫藥組合物及其用途 |
CN112274525B (zh) * | 2020-12-04 | 2022-04-08 | 遵义医科大学 | 一种化疗药物组合物及其应用 |
CN112336725A (zh) * | 2020-12-11 | 2021-02-09 | 吴照球 | 甲氧苄啶的医药新用途 |
CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN112569215A (zh) * | 2020-12-30 | 2021-03-30 | 东莞市人民医院 | 度米芬在制备防治结直肠癌的药物中的应用 |
EP4108244A1 (en) * | 2021-06-25 | 2022-12-28 | Universität Regensburg | Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies |
CN113663071B (zh) * | 2021-06-28 | 2022-12-30 | 四川大学 | Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途 |
WO2023006954A1 (en) | 2021-07-30 | 2023-02-02 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Asenapine for use in cancer |
WO2023035200A1 (zh) * | 2021-09-09 | 2023-03-16 | 中国福利会国际和平妇幼保健院 | 五氟利多在制备治疗子宫内膜癌的药物中的应用 |
CN115887455B (zh) * | 2022-08-04 | 2024-04-05 | 北京大学人民医院 | 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用 |
CN115778957B (zh) * | 2022-11-04 | 2024-06-21 | 天津中医药大学 | 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用 |
CN116570579A (zh) * | 2023-06-13 | 2023-08-11 | 深圳市泛谷药业股份有限公司 | 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用 |
CN118059099B (zh) * | 2024-04-19 | 2024-06-14 | 四川大学华西医院 | 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3844491B2 (ja) * | 1993-10-01 | 2006-11-15 | シンテックス(ユー・エス・エイ)インコーポレイテッド | ミコフェノール酸モフェチル高用量経口用懸濁剤 |
CA2207333C (en) * | 1994-12-28 | 2006-10-17 | Janssen Pharmaceutica, Naamloze Vennootschap | Use of nebivolol as an anti-atherogenic |
SI1113797T1 (sl) * | 1998-09-15 | 2010-02-26 | Lilly Co Eli | Uporaba duloksetina pri zdravljenju fibromialgije |
US6927223B1 (en) * | 2000-05-26 | 2005-08-09 | Washington State University Research Foundation | Use of serotonin agents for adjunct therapy in the treatment of cancer |
KR100699390B1 (ko) * | 2000-07-07 | 2007-03-28 | 트러스티즈 오브 터프츠 칼리지 | 9-치환된 미노사이클린 화합물 |
IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
US20040072824A1 (en) * | 2001-06-01 | 2004-04-15 | Adam Telerman | Methods and compositions for the treatment of cancer |
GB0202337D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Birmingham | Cancer treatment |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
WO2005027842A2 (en) * | 2003-09-18 | 2005-03-31 | Combinatorx, Incorporated | Combinations of drugs for the treatment of neoplasms |
AU2004288714A1 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
KR100775549B1 (ko) * | 2004-05-12 | 2007-11-16 | 주식회사바이오러넥스 | 나이아신아마이드 또는 그의 유도체를 유효한 성분으로포함하는 암 예방 및 치료제 |
KR101171408B1 (ko) * | 2004-05-21 | 2012-08-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 테트라사이클린 및 이의 유사체의 합성 |
CN1279980C (zh) * | 2004-10-14 | 2006-10-18 | 孔庆忠 | 一种抗实体肿瘤药物组合物 |
JP2006298781A (ja) * | 2005-04-15 | 2006-11-02 | Geno Membrane:Kk | エストロン3硫酸トランスポーター活性阻害剤 |
TW200716141A (en) * | 2005-05-05 | 2007-05-01 | Combinatorx Inc | Compositions and methods for treatment for neoplasms |
CN101223149A (zh) * | 2005-07-05 | 2008-07-16 | 特瓦制药工业有限公司 | 制备缬沙坦的方法 |
EP1909778B1 (en) * | 2005-07-28 | 2017-12-13 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Monophenol, benzenediol, or sulfhydryl compounds for use in the treatment of melanomas |
US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
CA2645494C (en) * | 2006-03-23 | 2016-01-12 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
CN101099724A (zh) * | 2006-07-07 | 2008-01-09 | 上海复旦复华药业有限公司 | 一种微粉化来曲唑及其组合物 |
CN101103976A (zh) * | 2006-07-14 | 2008-01-16 | 海南盛科生命科学研究院 | 一种含阿那曲唑的口服药物组合物及其制备工艺 |
MX2009007247A (es) * | 2007-01-05 | 2009-09-18 | Cornerstone Therapeutics Inc | Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos. |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
AU2008269181B2 (en) * | 2007-06-21 | 2014-04-17 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
WO2009025854A1 (en) * | 2007-08-22 | 2009-02-26 | Burnham Institute For Medical Research | Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
CN100563645C (zh) * | 2007-12-06 | 2009-12-02 | 济南帅华医药科技有限公司 | 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂 |
WO2009126274A2 (en) * | 2008-04-08 | 2009-10-15 | New York University School Of Medicine | Methods and compositions for the treatment of cancers, such as melanomas and gliomas |
CN101569624A (zh) * | 2008-04-29 | 2009-11-04 | 石药集团中奇制药技术(石家庄)有限公司 | 氨氯地平在制备治疗细胞增生性疾病药物中的用途 |
EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
WO2009147169A1 (en) * | 2008-06-03 | 2009-12-10 | Universite Paris Diderot-Paris 7 | Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia |
CN101612400A (zh) * | 2009-07-22 | 2009-12-30 | 陈志龙 | 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用 |
CN101690816A (zh) * | 2009-08-16 | 2010-04-07 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
CN101991553B (zh) * | 2009-08-21 | 2015-02-25 | 北京以岭生物工程技术有限公司 | 一种依西美坦片及其制备方法 |
CN101863806B (zh) * | 2010-03-18 | 2013-02-13 | 湖北省医药工业研究院有限公司 | 抗前列腺癌药物(r)-比卡鲁胺的制备方法 |
US9012511B2 (en) * | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
US9018438B2 (en) * | 2010-07-29 | 2015-04-28 | Kyoto University | Screening method for anticancer drugs |
WO2012079232A1 (zh) * | 2010-12-15 | 2012-06-21 | Lai Hung-Cheng | 用于治疗癌症的化合物及其应用 |
CN102631354B (zh) * | 2011-02-11 | 2015-01-21 | 广东泰禾医药科技有限公司 | 含维生素d3和二甲双胍的药物组合物 |
CN102688493B (zh) * | 2011-03-25 | 2014-09-10 | 鼎泓国际投资(香港)有限公司 | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 |
CN102813643B (zh) * | 2011-06-10 | 2014-09-24 | 北京蛋白质组研究中心 | bumetanide在抑制肝癌细胞转移中的应用 |
WO2013049045A1 (en) * | 2011-09-27 | 2013-04-04 | Biomed Valley Discoveries, Inc. | Compositions and methods of treating gliomas |
AU2012335009B2 (en) * | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
CN102600077B (zh) * | 2012-03-29 | 2013-06-05 | 江苏豪森药业股份有限公司 | 吉西他滨或其盐纳米乳剂注射液及其制备方法 |
ES2384069B1 (es) * | 2012-03-29 | 2013-07-04 | Hospital Sant Joan De Déu | Cinacalcet y tumores neuroblásticos |
CN103536607A (zh) * | 2012-07-10 | 2014-01-29 | 邵金辉 | 土霉素,普罗帕酮和安乃近的抗肿瘤作用 |
WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
WO2014036654A1 (en) * | 2012-09-06 | 2014-03-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
BR112015006176B1 (pt) * | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular |
EA037368B1 (ru) * | 2012-10-04 | 2021-03-19 | Аб Сьянс | Способ лечения рака поджелудочной железы у пациента, страдающего от связанной с болезнью интенсивной боли, и применение набора, содержащего маситиниб или его фармацевтически приемлемую соль и гемцитаниб, для лечения рака поджелудочной железы |
CN103356687B (zh) * | 2012-10-19 | 2016-06-01 | 厦门大学 | 一种伊维菌素及其衍生物的用途 |
WO2014108571A2 (en) * | 2013-01-14 | 2014-07-17 | Biocopea Limited | Cancer drug and uses |
CN103933569B (zh) * | 2013-01-22 | 2017-01-11 | 复旦大学 | 一种抗肺癌药物组合物及其应用、药盒和包装件 |
US9890127B2 (en) * | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
US20140271727A1 (en) * | 2013-03-18 | 2014-09-18 | National Yang-Ming University | Method of using an antidepressant for increasing immunity of a subject and treating cancer |
CN104161759B (zh) * | 2013-05-16 | 2019-10-08 | 中国科学院上海药物研究所 | 阿那格雷及其衍生物的抗肿瘤用途 |
CN103396419A (zh) * | 2013-08-13 | 2013-11-20 | 海宁市绿升医药科技有限公司 | 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法 |
CN103536925B (zh) * | 2013-10-28 | 2015-07-01 | 中国医学科学院基础医学研究所 | 强心苷化合物在非小细胞肺癌治疗中的应用 |
CN103622975B (zh) * | 2013-11-07 | 2016-06-15 | 广东药学院 | 格列吡嗪在制备治疗肿瘤药物中的应用 |
WO2015157471A1 (en) * | 2014-04-08 | 2015-10-15 | The Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
WO2016062277A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 驱虫药用于制备抗癌医药组合物中的应用 |
-
2015
- 2015-10-23 WO PCT/CN2015/092746 patent/WO2016062277A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092782 patent/WO2016062291A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092714 patent/WO2016062275A1/zh active Application Filing
- 2015-10-23 AU AU2015335375A patent/AU2015335375B2/en active Active
- 2015-10-23 WO PCT/CN2015/092653 patent/WO2016062267A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092775 patent/WO2016062285A1/zh active Application Filing
- 2015-10-23 TW TW104134963A patent/TW201615224A/zh unknown
- 2015-10-23 WO PCT/CN2015/092771 patent/WO2016062283A1/zh active Application Filing
- 2015-10-23 US US15/521,500 patent/US20170312260A1/en not_active Abandoned
- 2015-10-23 TW TW104134936A patent/TWI621434B/zh active
- 2015-10-23 ES ES15852557T patent/ES2973279T3/es active Active
- 2015-10-23 WO PCT/CN2015/092761 patent/WO2016062279A1/zh active Application Filing
- 2015-10-23 KR KR1020177011094A patent/KR102490334B1/ko active IP Right Grant
- 2015-10-23 WO PCT/CN2015/092702 patent/WO2016062274A1/zh active Application Filing
- 2015-10-23 US US15/521,524 patent/US20170304286A1/en not_active Abandoned
- 2015-10-23 TW TW104134942A patent/TW201615195A/zh unknown
- 2015-10-23 TW TW104134956A patent/TW201615196A/zh unknown
- 2015-10-23 US US15/521,536 patent/US20170304388A1/en not_active Abandoned
- 2015-10-23 CN CN201580057616.5A patent/CN107106550A/zh active Pending
- 2015-10-23 JP JP2017522418A patent/JP6539345B2/ja active Active
- 2015-10-23 TW TW104134924A patent/TW201615218A/zh unknown
- 2015-10-23 WO PCT/CN2015/092666 patent/WO2016062269A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092780 patent/WO2016062289A1/zh active Application Filing
- 2015-10-23 EP EP15852557.6A patent/EP3210604B1/en active Active
- 2015-10-23 WO PCT/CN2015/092686 patent/WO2016062271A1/zh active Application Filing
- 2015-10-23 TW TW104134959A patent/TW201615223A/zh unknown
- 2015-10-23 WO PCT/CN2015/092777 patent/WO2016062287A1/zh active Application Filing
- 2015-10-23 TW TW104134960A patent/TW201615191A/zh unknown
- 2015-10-23 TW TW104134944A patent/TW201615219A/zh unknown
- 2015-10-23 WO PCT/CN2015/092781 patent/WO2016062290A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092753 patent/WO2016062278A1/zh active Application Filing
- 2015-10-23 US US15/521,540 patent/US10098852B2/en active Active
- 2015-10-23 TW TW104134950A patent/TWI663969B/zh active
- 2015-10-23 WO PCT/CN2015/092779 patent/WO2016062288A1/zh active Application Filing
- 2015-10-23 ES ES15852781T patent/ES2954860T3/es active Active
- 2015-10-23 EP EP15852781.2A patent/EP3222278B1/en active Active
- 2015-10-23 EP EP15851742.5A patent/EP3235497A4/en not_active Withdrawn
- 2015-10-23 TW TW104134946A patent/TWI663984B/zh active
- 2015-10-23 AU AU2015335391A patent/AU2015335391B2/en active Active
- 2015-10-23 WO PCT/CN2015/092632 patent/WO2016062266A1/zh active Application Filing
- 2015-10-23 US US15/521,517 patent/US10105357B2/en active Active
- 2015-10-23 WO PCT/CN2015/092677 patent/WO2016062270A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092776 patent/WO2016062286A1/zh active Application Filing
- 2015-10-23 CN CN201580057095.3A patent/CN106999470A/zh active Pending
- 2015-10-23 TW TW104134961A patent/TW201615193A/zh unknown
- 2015-10-23 TW TW104134940A patent/TW201615186A/zh unknown
- 2015-10-23 WO PCT/CN2015/092697 patent/WO2016062272A1/zh active Application Filing
- 2015-10-23 TW TW104134908A patent/TWI672150B/zh not_active IP Right Cessation
- 2015-10-23 TW TW104134964A patent/TW201615225A/zh unknown
- 2015-10-23 TW TW104134952A patent/TW201615221A/zh unknown
- 2015-10-23 TW TW104134933A patent/TWI652060B/zh active
- 2015-10-23 TW TW104134966A patent/TW201615194A/zh unknown
- 2015-10-23 US US15/521,504 patent/US20170304228A1/en not_active Abandoned
- 2015-10-23 WO PCT/CN2015/092617 patent/WO2016062265A1/zh active Application Filing
- 2015-10-23 TW TW104134928A patent/TW201615197A/zh unknown
- 2015-10-23 TW TW104134945A patent/TW201615188A/zh unknown
- 2015-10-23 TW TW104134965A patent/TW201615226A/zh unknown
- 2015-10-23 WO PCT/CN2015/092768 patent/WO2016062281A1/zh active Application Filing
- 2015-10-23 CN CN201580057615.0A patent/CN107106523A/zh active Pending
- 2015-10-23 TW TW104134954A patent/TW201615222A/zh unknown
-
2017
- 2017-04-20 US US15/492,859 patent/US10045962B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI672150B (zh) | 抗生素藥物臨床新應用 | |
EP2802209B1 (en) | Otic formulations | |
Beena et al. | Antituberculosis drug research: a critical overview | |
KR20150115837A (ko) | 유방염을 포함하는 미생물 감염의 치료방법 | |
CN111821306A (zh) | Mdm2抑制剂和其组合 | |
JP2016529285A5 (zh) | ||
US10722550B2 (en) | Compositions and methods for the treatment of fungal infections | |
US20150267258A1 (en) | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients | |
ES2972618T3 (es) | Composición antibacteriana de combinación y régimen antibacteriano de corta duración que comprende linezolid, bedaquilina y pretomanida | |
JP2011514902A (ja) | 抗感染剤の安定な液体配合物および調節した抗感染剤投与計画 | |
WO2017019279A1 (en) | Methods and compositions to treat cancers involving egfr | |
US20230115867A1 (en) | Pemafibrate Dosing Regimens | |
Curebal et al. | Intraventricular tigecycline for the treatment of shunt infection: a case in pediatrics | |
US20180064710A1 (en) | Antifungal treatment of psoriasis | |
EP3710433A1 (en) | Cancer therapy by degrading dual mek signaling | |
US20080139545A1 (en) | Formulation to treat ear infection | |
TW200403072A (en) | Combination therapy for the treatment of bacterial infections | |
US20150297588A1 (en) | Sterile otic formulations | |
ATE395043T1 (de) | Amoxycillin und clavulanat enthaltende pharmazeutische brausefromulierung | |
WO2023212291A1 (en) | Treatment of pathogenic neisseria sp. infection with triazole antifungal agents | |
Rasmussen et al. | Penicillin concentrations in bone and subcutaneous tissue: A porcine microdialysis study comparing oral and intravenous treatment | |
Abugaa et al. | Supplementary info: Quality control results of drugs analyzed in DARU during the period 2016-2020 | |
CN104434948A (zh) | 一种抗胰腺癌的药物组合物及其应用 | |
Schriever et al. | Antimicrobial Agents | |
McKenzie | Respiratory antimicrobial therapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |